AstraZeneca plc (ADR) (NYSE:AZN) has revealed the Q1 financial results for 2014. Astra has reported promising results portray that the company has a better future in terms of growth and revenue. AstraZeneca plc (ADR) (NYSE:AZN) stock opened today at $78.06 and is currently trading at $77.80. The stock showed a negative weekly performance of -4.67%.
MannKind Corporation (NASDAQ:MNKD) will post its first quarter 2014 quarterly earnings on Monday May 12. Analysts estimate the company will post losses of 13 cents per share for the quarter. On average, analysts expect the company to post losses of 35 cents per share for the full fiscal year and losses of 20 cents per share for the next fiscal year. MannKind Corporation (NASDAQ:MNKD) stock opened at $6.25, in current trading session and currently is at $6.31, by gaining 1.53%. The 52 week range of $3.80 – $8.70. Company’s market capitalization is 2.43 billion.
Depomed (NASDAQ:DEPO) announced its earnings results on Thursday. The company reported ($0.01) earnings per share for the quarter, missing the analysts’ consensus estimate of $0.10 by $0.11, AnalystRatings.Net reports. The company had revenue of $76.50 million for the quarter, compared to the consensus estimate of $53.57 million. Depomed Inc. (NASDAQ:DEPO) stock is currently trading at $11.76. The EPS of the stock is 1.14. Company’s market capitalization is 679.59 million.
Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2014. For the first quarter of 2014, net sales decreased by approximately 14% to $19.1 million, compared to $22.1 million for the same period in the prior year. Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) stock opened the session at $4.65, and now is at $5.00. The 52 week range of the Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) stock remained $1.68 – $6.02 and the day range was $4.35 – $5.19.
Rexahn Pharmaceuticals Inc. (NYSEMKT:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer announced additional data from preclinical studies on the anti-tumor effects of RX-3117 a next generation cancer cell specific nucleoside analog. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) stock opened today at $0.80 and is currently trading at $0.800. The stock showed a negative weekly performance of -7.06%.